Background: The leading cause of death in under 16 years old children is by accident. A correct assessment for traumatic severity will help clinicians having an appropriate treatment and improving pediatric mortality. Objectives: To assess the prognostic validity of indicators Pediatric Trauma Score (PTS), Coma Glassgow Scale (CGS) and Revised Trauma Score (RTS) during short term for pediatric trauma. Subjects and method: Using the 3 indicators to evaluate traumatic severity in 92 patients (34 female, 58 male) at the age of 1 month olds to 15 year olds, treated in emergency unit from January, 1993 to May, 1994 in CHRU de Lille. Results: There are 2 main accidents as traffic accident (70%) and fall (25%). Traumatic mechanisms are closed trauma (69%), cranial trauma (80%), orthopedic trauma (33%), chest trauma (18%), abdominal trauma (21%). CGS indicator is more sensitive but less specific than the other two indicators. Its predictive validity is significantly higher than the validity of PTS or RTS. The probability of hospitalized patients with CGS<6, when discharging with complication is 100%. Conclusion: CGS indicator and improvement of it is appropriate to children. It is the most suitable in short-term predicting the possibility of complications. PTS and RTS indicators seem to be better on evaluating preliminary traumatic severity.
Wounds and Injuries/diagnosis ; Child ;

The possibility that patients with infantile nystagmus achieve spatial constancy by sampling the visual scene only during certain range of velocities or certain phases of their nystagmus cycle was investigated by asking patients to detect a flashed test target that was presented repeatedly during all phases of the nystagmus cycle. After observing a 543 nm fixation spot projected on a diffusely illuminated tangent screen 1 m in front of the eye, patients were asked to detect a 2 msec test flash of the spot, now locked to the retina, that occurred 200 msec after the fixation spot was extinguished. The test target appeared randomly at 3,6,9, or 12 o'clock at, in separate trials, 0.8 deg or 10.0 deg from central vision. To avoid forcing patients from guessing a direction cued by the disappearance of the fixation spot, sometimes the flash did not occur at all. To avoid dark adaptation in our patients, the diffuse background illumination was adjusted to the brightest level allowing easy detection of the test flash. In every condition, all patients reported the fixation spot stationary. The probability of detection was the same across all velocity ranges. Remarkably, patients were just as likely to detect the test flash when the eye was nearly stationary even when it was moving more than 100 deg/sec. In one patient, the background illumination was raised so that he began missing the test flash more often. Here too, the probability of detection, now reduced to about 50%, was the same across velocity ranges. In some patients we tried to backward mask the test flash by having the fixation spot reappear at various time after the test flash (40-2000 msec). Detection probability was unaffected by the reappearance of the fixation spot with the time interval tested. We conclude that the absence of oscillopsia in our patients was not accomplished by a sampling or masking process.
Adolescent ; Adult ; Eye Movements ; Female ; Humans ; Male ; Middle Aged ; Nystagmus, Pathologic/congenital/*physiopathology ; Photic Stimulation ; *Visual Perception

Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. Hence, physicians and nurses should actively engage in constructive discourse with their patients regarding HRT while specifically reviewing the potential risks of its extended use as well as provide the available medical alternatives the patients could potentially use.

Objective: The purpose of this study was to assess the efficacy and tolerability of a paclitaxel, carboplatin and metformin regimen in the first-line treatment of advanced-stage ovarian, fallopian tube, and primary peritoneal carcinoma. Methods: Eligible subjects underwent surgery and 6 cycles of neoadjuvant or adjuvant dose-dense intravenous paclitaxel (80 mg/m2), carboplatin (area under the curve 5 or 6 on Day 1), and oral metformin (850 mg daily). Study participants who completed their primary therapy and attained a clinically defined complete or partial response (PR) were treated with a planned 12 cycles of paclitaxel (135 mg/m2 every 21 days) and metformin (850 mg twice daily) maintenance therapy. Results: Thirty subjects received a median of 6 cycles (range, 5–6) of primary induction chemotherapy and were eligible for response evaluation; twenty-three patients exhibited a complete response, while 3 study patients obtained a PR (an overall response rate of 86.7%). Grade 3–4 hematological toxicity included neutropenia (43.3%), thrombocytopenia (10%) and anemia (36.7%). There was no incidence of grade 3–4 neuropathy although 15 patients (50%) developed grade ≤2 neurotoxicity. Additionally, we observed grade ≤2 diarrhea in 20 (66.7%) subjects. The median progression-free survival was 21 months (range, 3–52) and overall median survival was 35 months (range, 15–61). The subjects also received an aggregate 103 cycles (median, 12; range, 6–12) of maintenance chemotherapy. Conclusion The study results suggest that the combination of paclitaxel, carboplatin and metformin is associated with moderate efficacy and a reasonable toxicity profile.

OBJECTIVE: The risk factors associated with early ventral site hernia development following cancer surgery are ill defined and associated with an undetermined incidence. METHODS: We analyzed 1,391 gynecologic cancer patient charts to identify the number of post-operative ventral site hernias over a nearly 6 year period. The following study variables were noted for evaluation: patient demographics, disease co-morbidity (hypertension, cardiovascular disease, diabetes), body mass index (BMI), treatment (e.g., chemotherapy regimen), intra-operative (e.g., bleeding) and postoperative (e.g., infection) complications, time to hernia development and length of hospital stay. RESULTS: Twenty-six gynecologic cancer patients who developed a post-operative ventral hernia and subsequently underwent herniorrhaphy by our gynecologic oncology service were identified. The patient group's overall time to initial hernia development was 11.23 months. Following a multiple regression analysis, we found that treatment (e.g., bevacizumab, liposomal doxorubicin or radiotherapy associated with compromised wound healing [p=0.0186] and disease co-morbidity [0.0432]) were significant prognostic indicators for an accelerated time to hernia development. Moreover, five patients underwent treatment associated with compromised wound healing and also had disease co-morbidity. In this sub-group, post-operative hernia development occurred more rapidly (3.8 months) than the overall group of patients. BMI and age did not impact time to hernia development (p>0.05). CONCLUSION: In the present gynecologic cancer patient series, a tendency for early post-operative hernia development appeared to coincide with treatment associated with compromised wound healing and disease co-morbidity. Gynecologic cancer surgeons should anticipate this potential complication and consider employing prophylactic intra-operative mesh to potentially prevent this condition.
Antibodies, Monoclonal, Humanized ; Bevacizumab ; Body Mass Index ; Cardiovascular Diseases ; Demography ; Doxorubicin ; Hernia ; Hernia, Ventral ; Herniorrhaphy ; Humans ; Incidence ; Length of Stay ; Risk Factors ; Wound Healing

OBJECTIVE: The purpose of this retrospective study was to assess the tolerability and efficacy of sequential chemotherapy and radiotherapy for the treatment of high risk endometrial cancer. METHODS: We conducted a retrospective study of previously untreated high risk endometrial cancer patients who received sequential chemotherapy and radiotherapy in accordance with the sandwich approach from June 2008 until June 2011. High risk endometrial cancer patients underwent complete surgical staging followed by adjuvant therapy encompassing sequential chemotherapy, radiation therapy and consolidation chemotherapy. RESULTS: The study analysis comprised 32 endometrial cancer patients. All subjects were treated with carboplatin and paclitaxel chemotherapy; currently, 186 cycles have been administered and 94% of patients have completed the planned number of cycles. Grade 3 neutropenia developed in 1 (3.1%) patient; there was no incidence of grade 4 neutropenia. Moreover, we observed grade 3 anemia in four (12.5%) patients and grade 4 anemia in one (3.1%) patient. One (3.1%) patient developed grade 3 thrombocytopenia; grade 4 thrombocytopenia was not observed. Five patients exhibited progressive disease, three of whom have since expired; mean progression free survival and follow-up were 17.4 months and 18.9 months, respectively. CONCLUSION: The preliminary results from our study suggest that the sandwich approach to treating high risk endometrial cancer patients is feasible. Hematologic toxicity was well tolerated and non-hematologic toxicity was mild and easily managed. Further study of this novel regimen in a larger patient population with extended follow-up is necessary.
Anemia ; Carboplatin ; Disease-Free Survival ; Endometrial Neoplasms ; Female ; Follow-Up Studies ; Humans ; Incidence ; Neutropenia ; Paclitaxel ; Retrospective Studies ; Thrombocytopenia